Bristol Myers Squibb (BMY) Tax Provisions (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Tax Provisions data on file, last reported at $561.0 million in Q1 2026.

• Tax Provisions for Q1 2026 came in at $561.0 million, up 10.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 246.35% YoY), and the FY2025 annual result was $2.3 billion, up 310.11% from the prior year.
• Tax Provisions improved to $561.0 million in Q1 2026 per BMY's latest filing, from $384.0 million in the prior quarter.
• Over five years, Tax Provisions peaked at $919.0 million in Q3 2025 and troughed at -$398.0 million in Q2 2024.
• A 5-year average of $303.2 million and a median of $404.0 million in 2022 frame the typical range for Tax Provisions.
• The sharpest annual moves came in 2023 and 2025: Tax Provisions tumbled 141.21% in 2023, then surged 287.88% in 2025.
• A 5-year view of Tax Provisions shows it stood at -$166.0 million in 2022, then surged by 46.99% to -$88.0 million in 2023, then surged by 212.5% to $99.0 million in 2024, then surged by 287.88% to $384.0 million in 2025, then soared by 46.09% to $561.0 million in 2026.
• Business Quant data shows BMY's Tax Provisions at $561.0 million in Q1 2026, $384.0 million in Q4 2025, and $919.0 million in Q3 2025.